Ampio Begins Phase 1 Clinical Trial of Inhaled Ampion For COVID-19 Patients With Respiratory Distress
October 28 2020 - 07:30AM
PR Newswire (US)
Alert
Print
Share On Facebook
ENGLEWOOD, Colo., Oct. 28, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today the Company has begun recruiting and enrolling patients in a Phase I multi-center, randomized, controlled trial for a total of 40 patients that will assess the safety and efficacy of inhaled Ampion added to the standard of care ("SOC") for COVID-19 infected patients hospitalized for respiratory distress. Dosing of patients will begin at Penrose Hospital in Colorado Springs, Colorado and will expand enrollment to other hospitals in the near future.

Ampio Pharmaceuticals Logo. (PRNewsFoto/Ampio Pharmaceuticals, Inc.) (PRNewsfoto/Ampio Pharmaceuticals, Inc.)

AMPE is enrolling patients. IPIX should not be far behind

IPIX A new experiment in a human lung epithelial cell line with the live (or wild type) virus showed that Brilacidin inhibited SARS-CoV-2 when administered post-infection. These results complement earlier RBL experiments in the same lung cell line that showed Brilacidin, when directly incubated with the live virus, exhibited potent inhibition. As Brilacidin is showing consistent and robust anti-SARS-CoV-2 activity across the viral lifecycle, the Company believes the drug could be used as a treatment for preventing infection with COVID-19, as well as for treatment of patients once infected.
: from "Globe Newswire 4 Aug press release

Not the usual care
In addition to remdesivir, the president has received a combination antibody treatment. It's a cocktail of two monoclonal antibodies. Antibodies act by recognizing specific germs — in this case, SARS-CoV-2, the virus that causes Covid-19 — and harnessing the immune system to fight them off.

"We are maximizing all aspects of his care, attacking this virus with a multi-pronged approach," Conley said. "He's the president, and I didn't want to hold anything back. If there was any possibility that it would add value to his care and expedite his return, I wanted to take it."
From : Erika Edwards Article today 3 Oct @ AOL.com

EyePoint Pharmaceuticals and Vision Center Network of America Sign Purchase Agreement for DEXYCU®
Date : 02/18/2020 @ 7:00AM
Source : GlobeNewswire Inc.
Stock : EyePoint Pharmaceuticals Inc (EYPT)
Quote : 1.83 0.05 (2.81%) @ 6:08PM

EMPM Technically,still a shell but not for long. This
process has been in the works for over a year and is
finnally coming to fruition. Most of us here have been
here a while accumulating at a much lower share prices
and are sitting on some nice gains. We have done our DD
and will still be holding when we uplist to the Nasdaq.

Shares are tightly held with a majority on restriction
until July. I am speculating we see dollars by then.

GLTY

The share price of Biocept, Inc. [NASDAQ: BIOC] inclined by $0.32, presently trading at $0.32. The company’s shares saw 41.49% gains compared to the lowest price in the period of the last 52 weeks, set at $0.23 recorded on 02/13/20. The last few days have been benevolent to the share price as BIOC fall by -4.00% during the last week, even though the stock is still down by -10.67% compared to -0.01 of all time high it touched on 02/10/20. However, the stock had a poor performance during the past 3 months, roughly losing -5.82%, while additionally dropping -69.21% during the last 12 months. Biocept, Inc. is said to have a 12-month price target set at $1.00. That means that the stock has a strong potential to acquire 0.68% increase from the current trading price.

Biocept, Inc. [NASDAQ:BIOC]: Analyst Rating and Earnings
Its stock price has been found in the range of 0.23 to 2.11. This is compared to its latest closing price of $0.32.

Biocentral
47m
$BIOC We are very pleased to make our Target Selector™ platform available for testing CSF, as a more rapid identification of molecular alterations in brain metastases can aid physicians in choosing the best treatment options for their patients with breast or lung cancer," said Michael W. Nall, Biocept's President and CEO. "Among the significant capabilities of our technology is its versatility, which enables applications in a variety of clinical situations and for use with multiple types of biofluids."

EMPM- train about to leave the station for Nasdaq. SAEAN EV Industries

PPCB Reverse split ( 500/1 ) and increase in outstanding shares
from 100,000,000 to 1 BILLION both happened recently. Usually preceeds
the conversion of toxic notes @ 60% of share price. Eagle will be the
winner here.

Rinse and Repeat about to begin IMO

GLTY

PPCB RS @ 500/1. Overdue notes due at a 60% premium. Increase in OS to
1 billion shares. Horrible 10Q IMO.

Additionally, Eagle Equities has the option to convert all or any amount of the principal face amount of the August 2018 Eagle Note, at any time, into shares of the Company’s common stock at a price equal to 60% of the lowest closing bid price (the “Closing Bid Price”) of the Company’s common stock as reported on the OTC Markets quotation system for the ten prior trading days, including the day upon which the Company receives a notice of conversion from Eagle Equities (the “Conversion Price”). However, in the event that the Company’s common stock is restricted by the DTC for any reason, the Conversion Price shall be lowered to 50% of the lowest Closing Bid Price for the duration of such restriction. If the Company fails to maintain a reserve of shares of its common stock at least four times the number of shares issuable upon conversion of the August 2018 Eagle Note for at least 60 days after the issuance of the August 28, 2018 Eagle Note.

More notes in default due in the latest disclosure.

IBIO BOOM!!!!

News should be a green Monday. AH volume in big blocks coming in @ .30

EMPM manipulation on the bid side. Mostly sells. a coordinated effort
and we can take 50K + shares in the blink of an eye and leave these folks wondering " what just happened ? " It will continue until news. glta

EMPM I am hoping the Koreans are buying and locking up the float
before news hits.

On January 7, 2019, the Company issued an 8% convertible promissory note, (the “Note”) in the principal amount of $150,000, pursuant to a Securities Purchase Agreement we entered into with the investor. The Note matures January 7, 2020. The Note is convertible into shares of the Company’s common stock beginning on the date which is 180 days from the issuance date of the Note, at a conversion price equal to the lesser of (1) the lowest trading price during the previous 20 trading day period ending on the last completed trading date prior to the date of the Note and (2) 65% multiplied by the average of the 3 lowest trading prices of the Company’s common stock during the 20 day trading period ending on the latest completed trading day of the common stock prior to the date of conversion of the Note. The note was funded on January 9, 2019, when the Company received proceeds of $133,250 after OID of $14,000, and disbursements for the lender’s transaction costs, fees and expenses of $2,750, which were recorded as discounts against the debt to be amortized into interest expense through maturity. The embedded conversion feature included in the note resulted in an initial debt discount and derivative liability of $111,500. For the nine months ended September 30, 2019, amortization of the debt discounts of $93,678 was charged to interest expense. As of September 30, 2019, the outstanding principal balance of the note was $150,000 with a carrying value as of September 30, 2019, of $115,428, net of unamortized discounts of $34,572.



On February 5, 2019, the Company issued an 8% convertible promissory note (the “Master Note”) in the aggregate principal amount of up to $165,000 in exchange for an aggregate purchase price of up to $148,500 with an original issue discount of $16,500 to cover the Investor’s accounting fees, due diligence fees, monitoring and other transactional costs incurred in connection with the purchase and sale of the Master Note, which is included in the principal balance of the Note. On February 8, 2019, the Investor funded the first tranche under the Master Note, and the Company received $49,500 ($47,500 after payment of $2,000 of the Investor’s legal fees) for this first tranche of $55,000 under the Master Note and on the same date, the Company issued the Note to the Investor. The Note is convertible into shares of the Company’s common stock, beginning on the date which is 180 days from the issuance date of the Master Note, at a conversion price equal to the lesser of (1) the lowest trading price during the previous 20 trading day period ending on the last completed trading date prior to the date of conversion of the Master Note and (2) 65% multiplied by the average of the 3 lowest trading prices of the Company’s common stock during the 20 day trading period ending on the latest completed trading day of the common stock prior to the date of conversion of the Master Note. The embedded conversion feature included in the Master Note resulted in an initial debt discount and derivative liability of $38,502. For the nine months ended September 30, 2019, amortization of the debt discounts of $29,964 was charged to interest expense. For the nine months ended September 30, 2019, the investor converted a total of $25,920 of the face value and $1,500 of fees into 5,720,000 shares of common stock. As of September 30, 2019, the outstanding principal balance of the Master Note was $29,080 with a carrying value as of September 30, 2019, of $13,042, net of unamortized discounts of $16,038.



On February 21, 2019, the Company issued a 12% convertible promissory note, (the “Note”) in the principal amount of $53,000, pursuant to a Securities Purchase Agreement we entered into with an investor. The Note matures 12 months after the date of issuance. The Note is convertible into shares of the Company’s common stock beginning on the date which is 180 days from the issuance date of the Note, at a conversion price equal to 61% multiplied by the average of the lowest two trading prices during the 15- trading day period ending on the last completed trading date in the OTC Markets prior to the date of conversion. The note was funded on February 22, 2019, when the Company received proceeds of $50,000 after disbursements for the lender’s transaction costs, fees and expenses of $3,000, which were recorded as discounts against the debt to be amortized into interest expense through maturity. The embedded conversion feature included in the note resulted in an initial debt discount and derivative liability of $44,331. For the nine months ended September 30, 2019, amortization of the debt discounts of $47,331 was charged to interest expense. For the nine months ended September 30, 2019, the investor converted a total of $53,000 of the face value and $3,180 of accrued interest into 9,179,824 shares of common stock. As of September 30, 2019, the outstanding principal balance of the note was $-0-.

Granted they have paid some notes off as seen above. Good start. By My calculation next conversion will be in the trips.

Ozop Surgical Corp.

319 Clematis Street

Suite 714

West Palm Beach, FL 33401



January __, 2020



NOTICE OF STOCKHOLDER ACTION BY WRITTEN CONSENT



Dear Shareholder:



This notice and the accompanying Information Statement are being distributed to the holders of record (the “Shareholders”) of the voting capital stock of Ozop Surgical Corp., a Nevada corporation (the “Company”), as of the close of business on December 26, 2019 (the “Record Date”), in accordance with Rule 14c-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the notice requirements of Chapter 78 of the Nevada Revised Statutes (the “NRS”). The purpose of this notice and the accompanying Information Statement is to notify the Shareholders of actions approved by our Board of Directors (the “Board”) and taken by written consent in lieu of a meeting by the holders of a majority of the voting power of our outstanding capital stock as of the Record Date (the “Written Consent”).



The Written Consent approved the following action:



• Effecting a one-for-one thousand (1:1,000) reverse stock split of the Company’s issued and outstanding shares of common stock, without reducing the number of authorized shares of common stock (the “Reverse Stock Split”).



The Written Consent is the only shareholder approval required to affect the Reverse Stock Split under the NRS, our Articles of Incorporation, as amended, or our Bylaws. No consent or proxies are being requested from our shareholders, and our Board is not soliciting your consent or proxy in connection with the Reverse Stock Split. The Reverse Stock Split will not become effective until at least 20 calendar days after the accompanying Information Statement is first mailed or otherwise delivered to the Shareholders. We expect to mail the accompanying Information Statement to the Shareholders on or about January 6, 2020.



Important Notice Regarding the Availability of Information Statement Materials in Connection with this Schedule 14C: We will furnish a copy of this Notice and Information Statement, without charge, to any shareholder upon written request to the address set forth above, Attention: Corporate Secretary.



WE ARE NOT ASKING YOU FOR A PROXY, AND YOU ARE REQUESTED NOT TO SEND US A PROXY.





Sincerely,



/s/ Michael D. Chermak

Michael D. Chermak

Chairman & Chief Executive Officer



The number of shares of common stock issued and outstanding immediately prior thereto will be reduced from approximately 192,573,422 shares (assuming this number of shares outstanding as of December 26, 2019, are outstanding immediately prior thereto) to approximately 192,574 shares of common stock (1:1,000 reverse stock split ratio) and (ii) proportionate adjustments will be made to the per-share exercise price and the number of shares covered by outstanding options and warrants, if any, to buy common stock, so that the total prices required to be paid to fully exercise each option and warrant before and after the Reverse Stock Split will be approximately equal. Except for adjustments that may result from the treatment of fractional shares, which will be rounded up to the nearest whole number, each shareholder will beneficially hold the same percentage of common stock immediately following the Reverse Stock Split as such shareholder held immediately prior to the Reverse Stock Split.



As part of the Reverse Stock Split, the number of authorized shares of common will not be reduced.

Toxic debt to cover is usually the reason ( dilution ) in pinkyland.
They are still using toxic notes to cover day to day operations.
2.5 B authorized shares will not be enough if they keep going down
this road again. starting to look like a rinse and repeat.

conversion of the next note with .0076 as a lowest avg ( guess ) would
be a shares conversion of .00494.

Revenue ramp-up underway with pathway to operating profit

WEST PALM BEACH, FL, Oct. 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Ozop Surgical Corp. (OZSC), a provider of premium surgical devices in the rapidly growing field of minimally invasive spine surgery (“Ozop” or the “Company”), today released the following corporate update on its recent progress and current developments. Ozop believes the license agreement with Spinal Resources, Inc. is exceeding Company expectations.

Some of the specific developments include:

· 3 new surgeons currently using its licensed products, with 2 more expected to schedule cases before year end.

· 2 new Distributors in the contract finalization stage, ramp up expected to start by year end.

· 3 hospital contracts, including one national agreement, in the finalization stage. Cases starting upon approval possibly as soon as December.

· 3 new product introductions, the first, a proprietary MIS system before the end of year.

· First member of its surgeon advisory board has joined, more updates to follow.

Michael Chermak, Chief Executive Officer of OZOP, commented, “Our primary objective is to achieve operational profitability at the earliest moment possible. Our path to this goal will be accomplished by a combination of maximizing current sales opportunities and reducing overhead wherever possible, and investing in inventory and product development to support our growing sales pipeline.”

About Ozop Surgical Corp.

Ozop Surgical, Corp. (www.ozopsurgical.com) invents, designs, develops, manufactures and distributes innovative endoscopic instruments, surgical implants, instrumentation, devices and related technologies, focused on spine, neurological and pain management procedures and specialties. Our focus is on economically disrupting the market with clinically equivalent or superior existing and new products resulting in immediate and significant savings for providers, payors and consumers. For more information please visit www.ozopsurgical.com.

VNDM is hiding their game. .0001 bid / .01 ask LOL. Everything in between
is a guess unless you have access.

LOL You broke your PROMISE :)

Promised? LOL

You Have a link to your assessment?

LOL then I guess it must be deeply discounted shares for financing

About time for VFIN to make an appearance IMO.

PMEA needs to start showing production or 5s will fall. How long have they had 30 units on backlog? The market reacts when a company can't deliver in a reasonable amount of time. Hence deep trips from a recent high of 26.

How many 3s did the company release into the market last week. Surely no one here is selling with all the opportunity (carrots) the company has hung out in front. LOL

A wise man once told me you will never go broke when you sell for a profit.

PMEA MMs won't let it run on forward looking statements without verification. Not enough buyers vs sellers on the news of a buyout
after PR stating they were looking to make an acquisition.

PMEA 100 plus % not bad for a few days work. 3s will be back IMO. Waiting patiently

PMEA May be some validity to your response. Does not change the toxic MMs
recent appearance. We will see when the financing deal is announced. They lost 30% of projected 25 million for 2017 (Dinelly) and April is fast approaching.

DTC chill still in effect as far as I have seen.

If VFIN shows up, stuckholders could be made in a flash. Just a thought

GLTY

Patience MMs have not shown their hands as of yet. My guess is the downward spiral continues.

VNDM is a toxic MM. When/if VFIN makes an appearance :(

My next buy is set @ .0004

911 trades are coming from IHUB member

AIMHO

VNDM in the house, &
7s could be overpriced soon

I would think the Attorneys put a gag order on them until
the deal with Dinelley is litigated.

http://www.stormaircraft.com/contact-us.php

Take a look at the top aircraft on left side of page

Not faulting you for sugar coating PMEA. Looks like they will have a hard time unveiling the prototype next quarter without a place to build it.

They closed a deal with a company that had been dissolved a year earlier?

CEO has some explaining to do before any interest comes back other than
the daily IHUBers.

NOTE: I still hold shares but risk is minimal. I feel for the ones who stated "they still hold 1s and 2s".

PMEA from .0026 down to .0007 with a majority being sold at the bid all the way down is not rocket science U.F. Has anyone checked the OTC website
lately? Still under maintenance?

Sousse, WY -- January 03, 2017 – InvestorsHub NewsWire -- Aircraft manufacturer PM&E, Inc. (OTC: PMEA) announced today that they have signed all required documents and have officially closed on their much anticipated partnership agreement with ultra-light gyrocopter manufacturer, DiNelly EXOGYRO.

CEO Joseph Bourne stated, "We are pleased to announce that our business relationship with DiNelly EXOGYRO is now intact and structured for mutual long-term success. With the closing of this agreement, it is now time to get to work aggressively promoting both of our product lines. Over the coming months, we will be expanding our work force to ensure that demand is being met for the eXoGyro ultra-light units and our signature line of EVADA Aircraft.

March 1 2017

Mr. Akid continued, "Joseph has stated from day one that we are building a company of integrity and will always ensure that we are as transparent as possible with our shareholders. With that in mind, we'd like to inform everyone today that we are in communication with our Lawyers to terminate the Letter of Intent finalized with DiNelly Distribution, Ltd, which as it turns out was legally dissolved as an operating entity on December 29, 2015. The lack of transparency in the original negotiations does not align with the type of company that we have in the works and therefore, all operations and communications with DiNelly will cease immediately, our Lawyers are assessing and evaluating the damages caused to us and rest assured that we will act in the best interest of all our shareholders"

We all lose? I think not if your the one who sold 5.3 @ 9 after buying them yesterday @ 7. 31% gain is not bad for a days work if you trade the bumps while many say hold a pink long term.

5.5 million back up @ 7

If there is no meat on the plate, 6s will start to fill. My educated guess

If/when the Vtwins show up, then it will be cellar boxed and close to over. Over 20 million sold at the bid .0007. I got my fills.

Can't hold the stinky pinks, they are for trading.

EVADA AIRCRAFT is actually developing the EVADA A4 model with several national and international partners, which marketing is planned in 2017.

This could be a key to what you ask. It has not been announced as of yet.

https://pitchengine.com/pitches/be80a021-4f9a-475a-bc69-2d0788020c03


Production facility is in Tunisia and operational. I would think it would
be more rational to bring the prototypes to North America for approval prior to investing millions in a facility. $500K could buy back 25-30%
of the float. $500K for a state of the art facility is peanuts compared to what it will cost to build/convert a space suitable for their needs.

Buyback at these levels will not be an option after the news starts
to hit the airwaves. PPS will hit .005 on news of a buyback. Halfway
to QB status.

$500K @ .002 will be $2.5 million at a .01. Short term investment with a 5 fold return. Makes better sense in the longterm IMO.

My thoughts are with GPL being dismissed as PMEAs financeer, toxic lender,
they have shares to unload from frontloading before deal was PRd. This is a good thing providing terms are favourable as stated by CEO with the new lender.

I hope some of the $500K investment is being used to buyback shares to the treasury. This coupled with contract news will send the pps to copperland. AIMHO

http://www.pme-holding.com/pmea-ir-events-calendar/

Auditted fins in April

Sounds like a better financing deal. :0)

TY :)